DEVELOPMENT AND OPTIMIZATION OF COATED TABLET CONTAINING AMLODIPINE AND VALSARTAN FOR HYPERTENSION TREATMENT
DOI:
https://doi.org/10.22159/ijap.2024v16i4.50984Keywords:
Amlodipine, Valsartan, Film-coated tablets, In vitro equivalence, HypertensionAbstract
Objective: To develop and optimize the formulation of coated tablets containing these Active Pharmaceutical Ingredients (APIs)with in vitro equivalence to that of original drug.
Methods: Design Expert and BCPharSoft OPT softwares were applied in the development and optimization of film-coated tablets of amlodipine 5 mg and valsartan 80 mg, in order to obtain a tablet formulation with in vitro equivalence to original drug, in three dissolution testing environments. Evaluating through appearance, identification, medium hardness, weight uniformity, in vitro equivalence, assay.
Results: An optimized formulation of film-coated tablets with in vitro equivalence to the referent drug was obtained. For the tablet core, it is composed of amlodipine besylate 6.94 mg (equivalent to 5 mg amlodipine) and valsartan 80 mg with excipients of 9.77% crospovidone XL, 2% aerosil, 2.75% magnesium stearate, 42.01% avicel PH 112, with a hardness of 70-90 N. The film-coating suspension comprises 4.75% Hydroxypropyl Methylcellulose 6cps (HPMC 6cps), 0.42% polyethylene glycol 6000 (PEG 6000), 0.84% talc, 1.77% titanium dioxide (TiO2), 0.12% yellow iron oxide, in 92.1% ethanol 96%-water (2:1).
Conclusion: In the current study, a film-coated tablet formulation with in vitro equivalence of two APIs to the original drug in all three environments was successfully developed and optimized. The obtained results are an important premise for the development of related generic drugs in the pharmaceutical market of developing countries, which not only reduces the product price but also help less wealthy patients in developing countries to better control the hypertension disease.
Downloads
References
Ramteke, M.; Kasture, A. Simultaneous UV-Spectrophotometric Method for the Estimation of Atenolol and Amlodipine Besylate in Combined Dosage Form. Indian J Pharm Sci2006, 68, 394, doi:10.4103/0250-474X.26665.
Campbell, N.R.C.; Paccot Burnens, M.; Whelton, P.K.; Angell, S.Y.; Jaffe, M.G.; Cohn, J.; Espinosa Brito, A.; Irazola, V.; Brettler, J.W.; Roccella, E.J.; et al. 2021 World Health Organization Guideline on Pharmacological Treatment of Hypertension: Policy Implications for the Region of the Americas. Lancet Reg Health Am2022, 9, None, doi:10.1016/j.lana.2022.100219.
Haque, S.M.; Alsawalha, M. ANALYTICAL METHODS FOR THE QUANTITATION OF AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM IN PHARMACEUTICAL DOSAGE FORM AND BIOLOGICAL FLUIDS. Int J App Pharm2019, 5–15, doi:10.22159/ijap.2019v11i3.32566.
Elliott, W.J.; Ram, C.V.S. Calcium Channel Blockers: Calcium Channel Blockers. The Journal of Clinical Hypertension2011, 13, 687–689, doi:10.1111/j.1751-7176.2011.00513.x.
Jin, J.; Cao, F.; Ping, Q.-N.; Zhang, C. Preparation and Dissolution of Compound Valsartan and Amlodipine Besylate Tablets. Chinese Journal of New Drugs2012, 21, 1806-1811+1825.
Ghobashy, M.M.; Alshangiti, D.M.; Alkhursani, S.A.; Al-Gahtany, S.A.; Shokr, F.S.; Madani, M. Improvement of In Vitro Dissolution of the Poor Water-Soluble Amlodipine Drug by Solid Dispersion with Irradiated Polyvinylpyrrolidone. ACS Omega2020, 5, 21476–21487, doi:10.1021/acsomega.0c01910.
Huynh, D.T.M.; Tran, V.-H.; T. Le, M.-N.; Huynh, V.-H.; Pham, D.T. Floating Tablets Incorporating Curcumin Solid Dispersion as a Potential Pharmaceutical Dosage Form for Stomach Cancer Treatment. J App Pharm Sc2022, doi:10.7324/JAPS.2023.114417.
Huynh, D.T.M.; Hai, H.T.; Hau, N.M.; Lan, H.K.; Vinh, T.P.; Tran, V.D.; Pham, D.T. Preparations and Characterizations of Effervescent Granules Containing Azithromycin Solid Dispersion for Children and Elder: Solubility Enhancement, Taste-Masking, and Digestive Acidic Protection. Heliyon2023, 9, e16592, doi:10.1016/j.heliyon.2023.e16592.
United States Pharmacopeial Convention The United States Pharmacopeia; Rockville, 2020;
Costa, P. An Alternative Method to the Evaluation of Similarity Factor in Dissolution Testing. International Journal of Pharmaceutics2001, 220, 77–83, doi:10.1016/S0378-5173(01)00651-2.
Abdoh, A.; Al‐Omari, M.M.; Badwan, A.A.; Jaber, A.M.Y. Amlodipine Besylate–Excipients Interaction in Solid Dosage Form. Pharmaceutical Development and Technology2004, 9, 15–24, doi:10.1081/PDT-120027414.
Badwar, M.R.; Borse, S.L.; Junagade, M.S.; Jadhav, A.G. FORMULATION AND EVALUATION OF MOUTH DISSOLVING TABLET OF AMLODIPINE BESYLATE. Int J App Pharm2019, 132–139, doi:10.22159/ijap.2019v11i4.31288.
Van Der Merwe, J.; Steenekamp, J.; Steyn, D.; Hamman, J. The Role of Functional Excipients in Solid Oral Dosage Forms to Overcome Poor Drug Dissolution and Bioavailability. Pharmaceutics2020, 12, 393, doi:10.3390/pharmaceutics12050393.
Behin Formulation and Characterization of Fast Disintegrating Tablets of Amlodipine Using Super-Disintegrants. J. App. Pharm. Sci.2012, doi:10.7324/JAPS.2012.2819.
Ramírez, D.G.; Robles, L.V. Contrasting the Crospovidones Functionality as Excipients for Direct Compression. Braz. J. Pharm. Sci.2015, 51, 155–171, doi:10.1590/S1984-82502015000100016.
Park, C.; Lee, J.H.; Jin, G.; Ngo, H.V.; Park, J.-B.; Tran, T.T.D.; Tran, P.H.L.; Lee, B.-J. Release Kinetics of Hydroxypropyl Methylcellulose Governing DrugRelease and Hydrodynamic Changes of Matrix Tablet. CDD2022, 19, 520–533, doi:10.2174/1567201818666210820101549.
Published
How to Cite
Issue
Section
Copyright (c) 2024 DUYEN THI MY HUYNH, TRUONG PHU VINH, TRAN DUNG TAM, MINH-NGOC T. LE, PHUOC-VINH NGUYEN
This work is licensed under a Creative Commons Attribution 4.0 International License.
